fatigue (n=22), nausea (n=14), anorexia (n=9), and thrombocytopenia (n=7) ( Table 3 ). Grade 3 toxicities were fatigue (n=3), thrombocytopenia (n=1), neutropenia (n=3), hypertension (n=1), and decreased white blood cell count (n=1). Two patients
Search Results
Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer
Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess
Guiding Lay Navigation in Geriatric Patients With Cancer Using a Distress Assessment Tool
Gabrielle B. Rocque, Richard A. Taylor, Aras Acemgil, Xuelin Li, Maria Pisu, Kelly Kenzik, Bradford E. Jackson, Karina I. Halilova, Wendy Demark-Wahnefried, Karen Meneses, Yufeng Li, Michelle Y. Martin, Carol Chambless, Nedra Lisovicz, Mona Fouad, Edward E. Partridge, Elizabeth A. Kvale, and the Patient Care Connect Group
distress at initial assessment were pain (408 of 5,254 cases reporting a cause of distress), balance/mobility difficulties (404 cases), and fatigue (399 cases; Figure 2A ). This breakdown was similar for formal and informal DTs. Patients with distress
Change Toward Healthier Lifestyles Is Associated With Better Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors
Ruth Elisa Eyl-Armbruster, Melissa S.Y. Thong, Prudence R. Carr, Lina Jansen, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, and Volker Arndt
, occupational and social aspects of relevance) and social functioning, 6 , 8 and less fatigue 5 , 6 , 8 in CRC survivors. However, most studies used a cross-sectional study design, and to the best of our knowledge, no study has investigated whether a change
HSR19-091: Incidence of Adverse Events Following Use of Different PARP Inhibitors: Systematic Review and Meta-Analysis
Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson
). Of 1,685 patients who received PARPi, incidence of any AE, regardless of grade, was 98.5% (95% CI, 97.2–99.2%). Common AEs were: nausea (incidence rate, 68.9% and 95% CI, 58.7%–77.5%), fatigue (56.3%, 45.3%–66.8%), anemia (46.3%, 37
CLO19-031: Immune Checkpoint Inhibitors: Optimization of Pharmacy Services in Toxicity Management
Olivia G. Fahey, Elizabeth N. Dow, Jennifer K. Piccolo, and Ticiana A. Leal
pharmacists were gastrointestinal (n=15) and dermatologic (n=6). Endocrine (n=7) and dermatologic (n=7) were the most common grade 1 or 2 irAEs identified by other providers. There were 4 grade 3 irAEs (endocrine, fatigue, liver, and pneumonitis) identified by
HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer
Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams
. Fatigue and distress were described by most women regardless of treatment, whereas arm swelling was reported only by women who had undergone surgery, and skin changes were reported primarily by women who received radiation therapy. Patients volunteered
HSR19-108: A Meta-Analysis of Randomized Controlled Trials (RCTs) for Efficacy and Safety of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) Adjuvant Therapy in High-Risk Renal Cell Cancer (RCC)
Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, and Manish Kohli
.90; 95% CI, 0.67–1.19). Use of TKIs was associated with significantly increased risk of drug toxicity. Increased risk of grade 3 or 4 adverse events (RR=5.110; 95% CI, 3.765–6.935), diarrhea (RR=10.725; 95% CI, 4.672–24.622), fatigue (RR=3.310; 95% CI, 1
CLO19-029: Dosing Patterns of Nilotinib Use in SIMPLICITY, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice
Jorge Cortes, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis, and Stuart L. Goldberg
baseline fatigue (OR=1.799; P =0.072). Conclusions: Most pts treated with 1L NIL were started on 300 or 400 mg (BID); however, 1 in 4 pts required a dose reduction, most often due to intolerance. Physicians at academic centers were more likely to reduce
A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister
The median number of treatment cycles delivered was 2 for both groups (ranges, <1–13 for Group A; <1–15 for Group B). The most common cetuximab-related adverse events (all grades) among treated subjects included rash, fatigue, and hypomagnesemia
Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma
Luxi Chen, John Davelaar, Srinivas Gaddam, Kambiz Kosari, Nicholas Nissen, George Chaux, Christopher Lee, Eric Vail, Andrew Hendifar, Jun Gong, Karen Reckamp, and Arsen Osipov
abdominal pain. He experienced a significant unintentional 35-pound weight loss over 6 months with associated fatigue, loss of appetite, abdominal pain, and light-colored stools. Physical examination findings were notable for scleral icterus and jaundice. In